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Abstract 
 
Cytarabine (ara-C), a major antileukemic agent, is phosphorylated in the cell to 
cytarabine triphosphate (ara-CTP), which then is partly incorporated into DNA.  
The drug incorporation into DNA poisons the extending primer against further 
incorporation of deoxyribonucleotides including dCTP, ultimately inhibiting DNA 
synthesis.  While intracellular ara-CTP concentration has been found to predict 
clinical outcome, cytotoxicity in vitro is determined primarily by the extent of 
drug incorporation into DNA.  However, clinically appropriate quantitation 
methods for ara-C at the DNA level have not been available.  We developed a 
sensitive new method for monitoring ara-C incorporated into DNA in vivo.  After 
DNA from leukemic cells was fractionated using the 
Schmidt-Thannhauser-Schneider method, it was degraded to constituent 
nucleosides to release ara-C, which was isolated from the nucleosides using 
HPLC and then measured by radioimmunoassay.  Recovery for DNA 
fractionation, ara-C release by degradation, and ara-C isolation were 92.0 ± 
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6.4%, 90.7 ± 9.4%, and 98.5 ± 1.4%, respectively.  The method was found to 
determine ara-C incorporation into DNA of ara-C-treated HL60 cells in vitro with 
minimal interassay variation.  The values determined were compatible with 
those determined by scintillation counting in parallel experiments using tritiated 
ara-C.  Our method could be used to monitor DNA-incorporated ara-C 
concentrations during ara-C therapy, together with plasma ara-C and 
intracellular ara-CTP concentrations.  ara-C incorporation into DNA appeared 
to be associated with intracellular retention of ara-CTP or persistence of plasma 
ara-C.  Thus, the present method is sensitive, accurate, precise, and may 
permit therapeutic drug monitoring at the DNA level for better individualization 
of antileukemic regimens. 
  
Key Words: Cytarabine; DNA incorporation; Cytarabine triphosphate; Acute 
leukemia; TDM; Individualization. 
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1. Introduction 
 
ara-C, a pyrimidine nucleoside analogue, is among the most effective 
anticancer agents for treatment of acute leukemia [1-3].  The drug offers 
flexibility of use including doses at 3 to 10 mg/m2 (low dose), 70 to 100 mg/m2 
(regular dose), and 1 to 3 g/m2 (high dose) more than a 1000-fold range [3-6].  
Mechanisms of bioactivation and action are uniform regardless of dose.  After 
being transported into leukemic cells, ara-C is phosphorylated to ara-C 
5'-monophosphate and then to ara-C triphosphate (ara-CTP) [7, 8].  A small 
portion of this ara-CTP is incorporated as a monophosphate into DNA strands 
during the S phase of the cell cycle [9, 10].  The drug incorporation into DNA 
poisons the extending primer against further incorporation of 
deoxyribonucleotides including dCTP, ultimately inhibiting DNA synthesis [7-10].  
Therefore, both intracellular ara-CTP and DNA-incorporated ara-C are 
metabolites critical to the drug’s action [7-10]. 
In in vitro studies, both intracellular ara-CTP and DNA-incorporated 
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ara-C correlated with the cytotoxic effect of ara-C [7-12].  However, the 
correlation between ara-C incorporated into DNA and cell death was more 
significant than that between ara-CTP and cytotoxicity [9-10, 13].  
Incorporation into DNA is also critical to the cytotoxic activity of fludarabine and 
gemcitabine [14], suggesting general importance of interactions between DNA 
and nucleoside analogues.  Clinically observed therapeutic efficacy correlated 
closely with intracellular ara-CTP during high-dose ara-C treatment [15-20].  At 
a regular dose, we developed a sensitive method and confirmed that the 
metabolite ara-CTP was crucial to therapeutic outcome [21-23].  As for 
DNA-incorporated ara-C, one report described an assay method and its use to 
monitor ara-C at the DNA level in the clinic [24].  Yet, no studies have been 
conducted subsequently, reflecting need for more suitable in vivo monitoring 
methods.  Therefore, DNA-incorporated ara-C measurement has not yet been 
evaluated for clinical efficacy despite its critical role for in vitro cytotoxicity.  
To determine the clinical significance of DNA-incorporated ara-C, a 
better method is needed for monitoring ara-C concentrations at the DNA level 
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accurately and sensitively in clinical samples.  Ideally the method would allow 
simultaneous measurement of intracellular ara-CTP and plasma ara-C.   
In the present study we developed a sensitive new method for 
monitoring ara-C incorporated into DNA in vivo.  The procedure included 
fractionation of DNA from leukemic cells (step 1), degradation of DNA to 
nucleosides to release ara-C (step 2), isolation of ara-C using HPLC (step 3), 
and measurement of ara-C by radioimmunoassay (step 4).  The present study 
focused first on validation of recovery for each step of the assay procedure.  
Next, accuracy and precision of the method were confirmed using cultured 
leukemic cells in vitro.  Last, clinical utility was demonstrated by applying the 
method to monitoring ara-C concentrations within the DNA of peripheral 
leukemic blasts obtained from patients receiving ara-C. 
 
2. Materials and Methods 
 
2.1. Chemicals and reagents   
ara-C, bacterial alkaline phosphatase (EC 3.1.3.1), snake venom 
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phosphodiesterase (EC 3.1.4.1), and DNase I (EC 3.1.21.1) were purchased 
from Sigma.  [5-3H] ara-C (30 Ci/mmol), [methyl-3H] thymidine (20 Ci/mmol), 
[5-3H] uridine (20 Ci/mmol), and [thymidine-methyl-3H]-DNA (0.2 µCi/μg) were 
purchased from Daiichi Pure Chemicals.  Tetrahydrouridine, a cytidine 
deaminase inhibitor, was obtained from Calbiochem-Novabiochem.  Charcoal 
was purchased from J. T. Baker Chemical.  Anti-ara-C serum was kindly 
supplied by Daiichi Pure Chemicals.  This antiserum did not cross-react with 
phosphorylated forms of ara-C, uracil arabinoside, cytidine, or deoxycytidine 
[25].  All other chemicals were of analytical grade. 
2.2. Preparation of leukemic cells 
Human leukemia HL-60 cells were cultured in RPMI1640 media with 
10% heat-inactivated fetal calf serum.  The cells (2 x 106/ml, 10 ml) were 
incubated with various concentrations of ara-C for the time periods indicated at 
37°C.  Cells then were washed twice with PBS and centrifuged (500 X g, 5 min, 
4°C) to collect the cell pellet. 
2.3. DNA fractionation from cells 
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To fractionate DNA from the cell pellet, the classical STS method was 
used with slight modification [26-28].  The cell pellet described above was 
added to 30 μl of 15% perchloric acid in a microcentrifuge tube.  The sample 
then was vortexed, cooled in an ice bath for 15 min, and centrifuged (15000 X g, 
30 sec, 4°C).  The supernatant (acid-soluble fraction) was discarded, while the 
precipitate was obtained as the acid-insoluble fraction.  To solubilize the RNA, 
the acid-insoluble fraction was resuspended in 100 µl of 0.4 N KOH and kept at 
room temperature for 4 h.  The sample then was mixed with 100 µl of 5% 
perchloric acid and 20 µl of 4 N HCl, followed by centrifugation (15000 X g, 30 
sec, 4°C).  After removal of the supernatant (RNA), the precipitate was mixed 
with 100 µl of 5% perchloric acid, and then heated at 92°C for 20 min to 
solubilize the DNA.  After centrifugation (15000 X g, 30 sec, 4°C), the 
supernatant was isolated as DNA while the precipitate (protein) was discarded.  
To assess DNA fractionation, a pellet of HL 60 cells (1x107 cells) mixed 
with 10 µl of [thymidine-methyl-3H]-DNA underwent extraction of the 
acid-insoluble fraction and the subsequent fractionation of DNA.  Radioactivity 
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of the fractionated DNA was compared with that of the DNA mixed with the cell 
pellet.  To further assess the fractionation procedure, cells (2x106/ml, 10 ml) 
were incubated with 20 µl of [methyl3-H]-thymidine or 3H-uridine for 5 h at 37°C.  
The cell pellet was subsequently fractionated into DNA, RNA, and protein, and 
radioactivity of each fraction was measured.   
2.4. ara-C release by degradation of DNA to nucleosides  
To release ara-C from DNA, the DNA was degraded to the 
corresponding nucleosides.  The DNA fraction described above was once 
added to 70 µl of 1N KOH, vortexed, and centrifuged (15000 X g, 30 sec, 4°C) 
to obtain the supernatant as the neutralized DNA.  The neutralized DNA 
solution then was mixed with 300 µl of 1 M Tris, 5 µl of 10 mM CaCl2, 5 µl of 10 
mM MgCl2, 250 U of DNase I, 60 µg of phosphodiesterase, 10 U of alkaline 
phosphatase, and 10 µl of 1mg/ml tetrahyrdouridine.  This mixture (pH 8) was 
incubated for 12 h at 42°C to digest the DNA to nucleosides. 
To confirm degradation, HL 60 cells (2 x 106/ml, 10 ml) were incubated 
with an aliquot of tritiated ara-C for 5 h at 37 °C, followed by fractionation of 
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DNA.  To separate ara-C, the DNA sample was spotted on a TLC sheet 
(POLYGRAM CEL 300 UV254, 20 cm x 20 cm x 0.1mm, Machery-Nagel) before 
or after the degradation procedure, and developed by a 2-propanol: ethyl 
acetate: water (2:2:1) solvent for 3 h.  Radioactivity of ara-C released from 
DNA after degradation was compared with that of ara-C-containing DNA before 
degradation.   
2.5. ara-C isolation using HPLC  
To isolate ara-C from other nucleosides, HPLC was employed.  
Nucleosides obtained as described above were injected onto a cation-exchange 
column (Partisil 10 SCX, 250 mm length x 4.6 mm inside diameter; Whatman) 
and eluted with 0.01 M ammonium formate (pH, 3.0) at a constant flow rate of 
1.5 ml/min, at ambient temperature.  ara-C was identified by its retention time 
(15.5 min) at 254 nm.  The ara-C fraction was collected from 13 min to 18 min 
for a 5-min interval, and then was freeze-dried overnight. 
2.6. ara-C measurement using radioimmunoassay 
To measure ara-C concentration, radioimmunoassay was carried out as 
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previously described [21, 25].  This was a competitive reaction between 
tritiated ara-C and unlabeled ara-C for binding the antiserum.  Briefly, the 
ara-C fraction obtained above (unlabeled, unknown for its concentration) was 
dissolved in 400 µl of 0.01 M phosphate buffer containing 0.5% bovine serum 
albumin and 0.9% NaCl (pH 7.4), 100 µl of anti-ara-C serum, and 100 µl of 
diluted tritiated ara-C (0.05 µCi).  The mixture was incubated for 3 h at 37°C to 
allow competition between the labeled and the unlabeled for binding the 
antibody.  To separate the bound and free ara-C, the sample was added to 1 
ml of dextran-coated charcoal (100 mg of dextran and 1000 mg of charcoal per 
100 ml of the phosphate buffer above), cooled for 30 min at 4°C, and 
centrifuged (15000 X g, 30 sec, 4°C).  The supernatant (the antibody-bound 
ara-C) was isolated, and its radioactivity was counted on the following day.  
The ara-C concentration of the sample was extrapolated in the standard curve 
that was drawn simultaneously using 10 independent known concentrations of 
ara-C.  The lower limit of quantitation for the radioimmunoassay was 0.1 pmol. 
2.7. Drug monitoring at the DNA level in the clinic 
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Blood samples were obtained with informed consent from four leukemic 
patients receiving ara-C.  The patients were diagnosed with leukemia or 
leukemic transformation of myelodysplastic syndrome by standard criteria with 
bone marrow examination.  All were refractory or relapsed.  In two patients 
(Nos. 3 and 4), plasma ara-C and intracellular ara-CTP concentrations were 
monitored simultaneously.  Each blood sample was placed in heparinized 
tubes containing tetrahydrouridine at a final concentration of 0.1 mM, layered 
over Ficoll-Hipaque, and centrifuged (500 X g, 30 min, room temperature) to 
separate plasma and leukemic cells [29, 30].  Plasma ara-C concentration was 
determined using the radioimmunoassay described above [21, 25].  Blasts 
were washed twice with PBS and then centrifuged (500 X g, 5 min, 4°C) to 
pellet the cells.  The pellet (2 x 107 cells) was divided into acid-soluble 
(supernatant) and acid-insoluble (precipitate) fractions by adding 30 μl of 15% 
perchloric acid.  The acid-insoluble fraction was used to measure ara-C 
incorporated into DNA as described above.  The acid-soluble fraction was 
used to measure intracellular ara-CTP as previously reported [21].  Briefly, the 
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acid-soluble fraction was neutralized with KOH and applied to an ion-exchange 
column (TSK gel DEAE-2 SW, 250 mm length x 4.6 mm inside diameter; 
TOSOH).  Elution was performed using 0.05 M Na2HPO4 (pH 6.9) - 20 % 
acetonitrile at a constant flow rate of 0.7 ml/min, at ambient temperature.  
ara-CTP was monitored spectrophotometrically at 269 nm, fractionated, and 
freeze-dried overnight.  After ara-CTP obtained was dephosphorylated 
enzymatically, the resulting ara-C was measured using the radioimmunoassay 
described above (Fig. 1). 
2.8. Measurement of DNA-incorporated ara-C and intracellular ara-CTP using 
tritiated ara-C   
 To verify the present method, cultured HL 60 cells or primarily obtained 
leukemic cells (2 x 106/ml, 10 ml) were incubated with tritiated ara-C in parallel 
experiments.  Cells then were washed twice with PBS, and centrifuged (500 X 
g, 5 min, 4°C).  The pellet was divided into acid-soluble and acid-insoluble 
fractions by adding 30 μl of 15% perchloric acid.  DNA was fractionated from 
the acid-insoluble fraction using the STS method, while ara-CTP was isolated 
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from the acid-soluble fraction using HPLC as described above.  Radioactivity 
of each metabolite was counted on the following day. 
2.9. Statistical analyses 
 All statistical analyses were performed with Microsoft Excel 2003 
(Microsoft Corporation).  All graphs, linear regression lines, and curves were 
generated using GraphPad Prism (version 4.0; GraphPad Software). 
 
3. Results 
 
3.1. Recovery in the assay steps 
Recovery was evaluated for the steps of DNA fractionation, ara-C 
release, and ara-C isolation.  To assess recovery at the step of DNA 
fractionation, the pellet of HL 60 cells was mixed with tritiated DNA, followed by 
the DNA fractionation procedure described in Materials and Methods.  
Radioactivity of DNA fractionated from the mixture was equal to that present in 
the tritiated DNA added to the cell pellet (Table 1).  To further confirm the 
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completeness of the fractionation procedure, the cells were incubated with 
tritiated thymidine or uridine, followed by fractionation into DNA, RNA, and 
protein as described in Materials and Methods.  Radioactivity in each fraction 
demonstrated clear separation and excellent recovery of DNA (Table 1).   
To assess recovery at the step of ara-C release, cells were incubated 
with tritiated ara-C to allow its incorporation into DNA.  The DNA then was 
fractionated from the cells and ultimately degraded to nucleosides as described 
in Materials and Methods.  TLC revealed that radioactivity of ara-C released 
from DNA after degradation was compatible with that of the ara-C-bearing DNA 
before degradation (Table 1).   
To assess recovery at the step of ara-C isolation, a mixture of tritiated 
ara-C and standard deoxyribonucleosides was eluted by HPLC.  ara-C 
(retention time; 15.5 min) was clearly separated from the other nucleosides 
(retention times; uracil arabinoside; 2.3 min, thymidine; 2.7 min, 
2'-deoxyguanosine; 6.5 min, 2'-deoxycytidine; 23.3 min, 2'-deoxyadenosine; 
34.8 min), and subsequently fractionated, lyophilized overnight, and recovered.   
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Radioactivity of the ara-C recovered was equal to that of the ara-C added to the 
mixture (Table 1).  Thus, recovery was excellent at each step in the present 
assay procedure, strongly supporting its practicability.  
3.2. Measurement of DNA-incorporated ara-C in biologic samples 
To evaluate accuracy, precision, and sensitivity of measurements in 
biologic samples, DNA-incorporated ara-C was quantitated in ara-C-treated HL 
60 cells using our assay.  Figure 2 demonstrates that DNA-incorporated ara-C 
increased both concentration- and time-dependently, reaching a plateau at 
concentrations of 5 to 10 μM or at incubation periods of 4 to 6 h.  As for 
interassay variability, the coefficient of variation was approximately 30% at each 
concentration (Table 2), suggesting appropriate precision despite the multistep 
nature of the method and the use of biologic materials.  The lower limit of 
quantitation, defined as the lowest concentration that gave a coefficient of 
variation less than 50%, was 1 pmol/1 x 107cells.  This limit permitted sufficient 
sensitivity to detect DNA-incorporated ara-C yielded by incubation with ara-C at 
0.5 μM (Fig. 2A), a concentration near the plasma concentration obtained 
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during continuous infusion of conventional-dose ara-C [23].  To evaluate 
accuracy of the method, ara-C concentrations at the DNA level measured by 
the present method were compared with those obtained using tritiated ara-C in 
the same experimental setting (Figs. 2A and B).  ara-C concentrations 
obtained by these two methods were quite similar to each other, with 
statistically significant correlation values (Figs. 2A and B, inset).  Thus, the 
present assay method was precise, accurate, and sensitive for quantitation of 
DNA-incorporated ara-C in biologic materials, strongly supportive of clinical 
applicability. 
3.3. Monitoring ara-C at the DNA level in the clinic 
To confirm clinical utility of the present method, TDM was conducted to 
determine ara-C incorporation into DNA in vivo in primarily obtained leukemic 
cells from patients receiving ara-C.  Table 3 presents DNA-incorporated ara-C 
concentrations during intermediate- and high-dose ara-C administration in four 
leukemic patients.  ara-C concentrations varied widely among patients, doses, 
and sampling time points.  Figures 3A and C present concentration-time 
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curves in two patients (Nos. 3 and 4), indicating comprehensive TDM of ara-C 
at the plasma, the cellular, and the DNA levels.  To confirm these monitored 
values, leukemic blasts obtained from the same two patients prior to 
chemotherapy were incubated in vitro with tritiated ara-C.  DNA-incorporated 
ara-C and intracellular ara-CTP concentrations were measured by scintillation 
counting (Figs. 3B and D).  Concentrations of both metabolites monitored in 
the clinic (Fig. 3A for patient 3, Fig. 3C for patient 4) were in the same range of 
those obtained in the culture media with added tritiated ara-C (Fig. 3B for 
patient 3, Fig. 3D for patient 4), supporting accuracy of this TDM.  Thus, the 
present assay method was capable of measuring ara-C concentration at the 
DNA level in leukemic cells from patients receiving ara-C chemotherapy.  The 
method provided measurements of intracellular ara-CTP and plasma ara-C 
concentrations at the same time (Figs. 1 and 3). 
 
4. Discussion 
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We presently described and validated a sensitive new method for 
monitoring ara-C concentrations at the DNA level in leukemic cells in vivo.  
Recovery at each step of the procedure was excellent (Table 1).  The method 
was sensitive for measuring DNA-incorporated ara-C in cultured leukemic cells 
treated with 0.5 to 10 μM ara-C in vitro (Fig. 2).  Values obtained were 
accurate, agreeing with those determined by scintillation counting using tritiated 
ara-C in parallel experiments (Fig. 2, inset).  Precision was confirmed by a 
minimal interassay variation despite the multistep nature of the process and the 
use of the biologic materials (Table 2).  The method was applied to monitoring 
DNA-incorporated ara-C concentrations in leukemic blasts from patients being 
treated with ara-C (Table 3, Fig. 3).  Monitored values were verified by 
comparison with values determined in the same sample of the patients’ cells 
before treatment using tritiated ara-C in vitro (Fig. 3).  The method adapted 
easily to simultaneous measurement of intracellular ara-CTP and plasma ara-C 
(Figs. 1 and 3).  Thus, the present assay was accurate, precise, and sensitive 
for clinical monitoring of ara-C concentrations at the DNA level. 
 19
A similar method developed by Spriggs et al. for quantitation of ara-C 
incorporated into DNA of leukemic cells [24] also used DNA fractionation from 
cells, HPLC separation of ara-C from DNA, and ara-C measurement using 
radioimmunoassay.  The major difference between their method and ours 
involved DNA fractionation.  Spriggs used enzymatic isolation with ethanol 
precipitation, while we employed the classical STS method.  The former was 
developed simply to isolate intact DNA from the cell, while the latter was 
developed for quantitation of DNA content in the entire cell [26-28, 31].  This 
suggests that the STS method should achieve better recovery of DNA from the 
cell than the enzymatic method [32].  Adoption of the STS fractionation should 
enable our method to obtain more DNA from samples and accurately measure 
lower concentrations of DNA-incorporated ara-C.  Our method also may be 
better suited to simultaneous measurement of intracellular ara-CTP and 
plasma ara-C concentrations.  Thus, our method was used to monitor drug 
concentrations at the DNA level over time during ara-C therapy; in contrast, no 
data obtained using the previous method have been reported since the initial 
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study. 
The present assay method monitored ara-C concentrations at the DNA 
level in circulating blasts from leukemic patients receiving ara-C (Table 3, Figs 
3A and C).  In patient 3 (Fig, 3A), concentrations of DNA-incorporated ara-C, 
intracellular ara-CTP, and plasma ara-C were greatest at the end of the infusion.  
All three forms of ara-C decreased gradually, and fell below the quantitation 
limit by 8 h after the infusion.  Elimination of DNA-incorporated ara-C appeared 
to be slower than that of intracellular ara-CTP, in agreement with previous in 
vitro results in which DNA-incorporated ara-C was more persistent than 
intracellular ara-CTP [13, 33, 34].  In patient 4 (Fig. 3C), both plasma ara-C 
and intracellular ara-CTP were maintained longer than in patient 3.  This 
appears to reflect our previous finding that maintenance of plasma ara-C was 
necessary for retention of ara-CTP in leukemic cells [22, 23].  Unlike that in 
patient 3, the DNA-incorporated ara-C concentration in patient 4 was even 
increased between 5 and 8 h after the end of the infusion (Fig. 3C).  This might 
be attributed to prolonged retention of ara-CTP in cells, since ara-C 
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incorporation into DNA requires intracellular ara-CTP formation [35, 36].  
Moreover, as maintenance of plasma ara-C is necessary for ara-CTP formation 
[22, 23], relatively slow elimination of plasma ara-C in patient 4 might be 
primarily responsible for prolonged incorporation of ara-C into DNA.  Thus, 
DNA incorporation of ara-C might depend in part on intracellular retention of 
ara-CTP or persistence of plasma ara-C.   
Intracellular ara-CTP concentrations in patient 3 (Fig. 3B) were similar 
to those determined in cultured HL 60 cells (30 – 300 pmol/1 x 107 cells) [34].  
However, ara-C concentrations at the DNA level in patient 3 (1 to 10 pmol/1 x 
107 cells, Fig. 3B) were much lower than those of HL 60 cells (10 to 80 pmol/1 x 
107 cells, Fig. 2A).  Because the extent of ara-C incorporation into DNA is 
cell-cycle dependent [7, 8, 11, 12, 35], greater ara-C incorporation into DNA of 
cultured cells may reflect a larger S-phase fraction than that in patient’s 
circulating blasts.  In relapsed leukemia, various mechanisms of ara-C 
resistance such as the increases in DNA polymerases [36] and in DNA 
exonuclease activity [37, 38] also may reduce DNA incorporation of the drug 
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despite intracellular retention of ara-CTP.  If so, the ara-C concentration at the 
DNA level may not always be proportional to the intracellular ara-CTP 
concentration and therefore not be entirely predictable from plasma or cellular 
pharmacokinetics.  Moreover, the DNA-incorporated ara-C concentration in 
patient 4 increased between 5 and 8 h after ara-C infusion while no further 
incorporation was observed at 5 h in patient 3 (Figs. 3A&C).  In addition to the 
pharmacokinetic consideration above, the ara-C concentration at the DNA level 
in patient 4 may not have been fully sufficient to terminate DNA chain 
elongation, thus allowing the drug to be incorporated further into the blasts’ 
replicating DNA.  This also suggested a possibility that individual patients may 
have different target drug concentrations at the DNA level for maximal inhibition 
of DNA synthesis.  Accordingly, DNA-incorporated ara-C may be worthy of 
pharmacokinetic evaluation as an independent parameter for prediction of 
therapeutic outcome with ara-C. 
A combination of regular-dose ara-C given for 7 days with daunorubicin 
given for 3 days has been a standard induction therapy for the last 20 years.  
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This regimen achieves complete remission rates of over 70% in adult patients 
with acute myeloid leukemia [1-3].  However, the remissions are not durable, 
and long-term survivors account for only 30% to 40% of patients.  Because 
achievement of complete remission is indispensable for long-term survival and 
cure, reinforcement of induction therapy may improve results in terms of both 
rate and quality of the remission.  Quality or depth of remission may differ 
among patients responding to the same induction regimen because their 
leukemic cells vary in drug sensitivity.  As ara-C is the key drug in remission 
induction therapy, quality of remission well may depend on sensitivity of the 
cells to ara-C.  Therapeutic outcome with ara-C has been closely associated 
with intracellular pharmacokinetics as opposed to the plasma ara-C 
concentration [15-20, 39, 40].  However, ara-C-induced cytotoxicity in vitro has 
been found to be determined primarily by the extent of incorporation of ara-C 
into DNA [13].  If this also is the case in the clinical setting, ara-C therapy may 
be individualized best according to the pharmacokinetics not only of intracellular 
ara-CTP but also of DNA-incorporated ara-C.  We have developed sensitive 
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techniques for clinically monitoring intracellular ara-CTP [21] and now also 
DNA-incorporated ara-C (Fig. 1).  Therapy for leukemia thus may be 
individualized based on TDM at the DNA level for ara-C.   
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Legends 
 
Fig. 1. Scheme for clinical monitoring of ara-C and metabolites.  Plasma 
ara-C, intracellular ara-CTP, and DNA-incorporated ara-C can be measured 
simultaneously in one blood sample.   
 
Fig. 2. Measurement of DNA-incorporated ara-C in biologic samples in vitro.  
HL 60 cells were incubated with various concentrations (0.5 μM, 1 μM, 2 μM, 5 
μM, and 10 μM) of ara-C for 6 h (A), or with 10 μM ara-C for the indicated time 
periods (2 h, 4 h, and 6 h) (B).  ara-C incorporated into DNA was measured 
using the present assay method (●).  Alternatively, the cells were incubated 
with tritiated ara-C in the same experimental setting, and ara-C incorporated 
into DNA then was determined by scintillation counting (o).  Inset: 
DNA-incorporated ara-C concentrations were compared between these two 
measurements for each experiment.  Ordinate, DNA-incorporated ara-C 
measured by the present method (pmol/1 x 107cells).  Abscissa, 
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DNA-incorporated ara-C measured by scintillation counting (pmol/1 x 107cells).  
r2 = 0.99, slope = 1.16, P < 0.0001 for Fig. 2(A) inset, r2 = 0.99, slope = 1.12, P 
< 0.0001 for Fig. 2(B) inset.  
 
Fig. 3. TDM during ara-C therapy.  (A) and (C), Concentration-time curves of 
plasma ara-C (*), intracellular ara-CTP (o), and DNA-incorporated ara-C (●).  
Leukemic patients (A; Patient 3, acute myeloid leukemia, M5b, C; Patient 4, 
plasma cell leukemia) were treated with 1-h intravenous infusion of 1 g/m2 
ara-C, and blood samples were collected at the indicated time points (before the 
treatment, 0 h, 1 h, 3 h, 5 h, and 8 h after the end of the infusion).  
Concentrations of ara-C incorporated into gemonic DNA of leukemic cells (●) 
were quantitated using the present method.  Concentrations of plasma ara-C 
(*) and intracellular ara-CTP of leukemic cells (o) were measured 
simultaneously.  (B) and (D), DNA-incorporated ara-C and intracellular 
ara-CTP concentrations in pretreatment leukemic cells (B; Patient 3, D; Patient 
4) exposed in vitro to ara-C.  Leukemic blasts were obtained prior to 
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chemotherapy from each patient, resuspended in fresh media, and incubated 
for 6 h with various concentrations (1 μM, 2 μM, 5 μM, and 10 μM) of tritiated 
ara-C.  Intracellular ara-CTP (o) and DNA-incorporated ara-C (●) were 
measured by scintillation counting.   
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2, DNA fractionation (2)
3, ara-C release
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Table 1 Recovery at each step
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1, A pellet of HL 60 cells mixed with tritiated DNA underwent the DNA fractionation procedure.  
Radioactivity of the fractionated DNA was compared with that of the DNA mixed with the cell pellet.  
2, Cells were incubated with tritiated thymidine or uridine, followed by fractionation into DNA, RNA, 
and protein.   Radioactivity of each fraction was measured.  3, Cells were incubated with tritiated
ara-C, and then DNA was fractionated from the cells and subsequently degraded to nucleosides.  
Radioactivity of ara-C released from DNA after degradation was compared with that of ara-C-
containing DNA before degradation.  4, Tritiated ara-C and standard deoxyribonucleosides were co-
eluted in HPLC.  ara-C was fractionated, lyophilized overnight, and recovered in 1 ml of water.  
Radioactivity of ara-C recovered was compared with that of ara-C applied to HPLC.  Values for 
recovery are the means ±SD of paired samples analyzed in triplicate.  
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Table 2 Interassay variation for quantitating ara-
C incorporated into DNA
1 
2 
5 
10 
Mean SD %CV
15
35
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63
4.0
7.1
22.4
18.8
27.2
20.2
36.5
29.9
HL 60 cells were incubated for 6 h with the indicated concentrations
of ara-C on three separate days.  Concentrations of ara-C 
incorporated into DNA (pmol/1 x 107cells) were measured using the 
present method.  CV; coefficient of variation. 
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Leukemic patients were treated with ara-C, and peripheral blasts were collected at indicated time points.  Concentrations of ara-C 
incorporated into DNA of leukemic cells were quantitated using the present method.  AML, acute myeloid leukemia; M2, M5b, subclass 
of leukemia by French-American-British classification; MDS-LT, leukemic transformation of myelodysplastic syndrome; WBC, peripheral
white blood cell; 1 h-iv inf, intravenous infusion for 1 h; 2 h-iv inf, intravenous infusion for 2 h; NE, not evaluated; ND, not detected 
(below the lower detection limit). *Sampling time points after the end of infusion.
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